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Abstract
The objective was to systematically review monetary data related to manage-
ment of incontinence-associated dermatitis (IAD) in an adult population. Six
electronic databases were searched: MEDLINE, CINAHL, Web of Science,
EMBASE, The Cochrane Library and EconLit. The search string combined
index terms and text words related to IAD and monetary data. The quality of
the articles was assessed using the consensus on Health Economic Criteria.
Results were synthesised narratively because of methodological heterogeneity.
Nine studies were included. Only direct medical costs were reported. The prod-
uct cost per application for prevention ranged between $0.05 and $0.52, and
for treatment between $0.20 and $0.35. The product cost per patient/day for
prevention ranged between $0.23 and $20.17. The product cost of IAD preven-
tion and treatment per patient/day ranged between $0.57 and $1.08. The cost
to treat IAD did not consider the treatment of secondary infection. The calcula-
tion of labour cost and total cost differed considerably between studies.
Summarising monetary data is a challenge because of heterogeneity in curren-
cies, settings, samples, time horizons, health- and cost outcome valuation, IAD
definition and measurements, and included costs. Procedures for health eco-
nomic evaluations are to be clarified to guarantee valid interpretation and
comparison with other studies.
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Incontinence-associated dermatitis (IAD) is an irritant
contact dermatitis resulting from prolonged contact of
the skin with urine and/or faeces.1 IAD is clinically
observed as erythema and edema of the skin, sometimes
accompanied by bullae with serous exudate, erosion, or
secondary cutaneous infection. IAD falls under the
umbrella term of moisture-associated skin damage
(MASD). Other types of MASD are intertriginous derma-
titis (ITD), peri-wound skin damage, and peri-stomal
MASD.2 IAD is an underreported health condition.3,4
Depending on the type of setting and population studied,
prevalence ranges between 7.6% and 45.7%.5-8 IAD is not
only a painful condition, it also increases the susceptibil-
ity to develop secondary skin infections (such as candidi-
asis and Pseudomonas aeruginosa), and deep wounds
such as pressure ulcers.9,10 Skin assessment, cleansing,
restoring, and protection of the barrier function are key
strategies to prevent and treat IAD. Skin care products
for IAD prevention/intervention can be divided into
cleansers, moisturisers, and skin protectants or a combi-
nation of those products.9,11
1.1.2 | Health economic evaluations
Consequences of IAD such as pressure ulcer develop-
ment, fungal infections and extra caregiver time needed
for skin care, impose a financial burden on organisations
and individuals. Economic and budget limitations, such
as nurse scarcities and a high staff turnover,12,13 urge
policy-makers to decide how to wisely spend appropriate
resources for maximum benefit. As a result of the
increased costs associated with IAD, insight in the mon-
etary data related to the prevention and treatment
regimens to best improve the condition is essential.14 A
distinction can be made between full economic and
partial economic evaluations. Full economic evaluations
(cost–benefit analysis, cost-utility analysis, cost-effective-
ness analysis, and cost-minimization analysis) compare
both costs and consequences (effectiveness; benefits) of
two or more interventions. Partial evaluations (costs
analysis, cost-outcome description, cost description, out-
come description, and cost-of-illness studies) consider
costs and/or consequences, but do not involve a compar-
ison between alternative interventions or do not relate
costs to benefits. Only full economic evaluations can
help answer questions related to efficiency, however,
partial evaluations can be useful because they can
deliver elements of information for a full evaluation.15,16
Health economic evaluations need to be clear about
the included costs; if it is direct- or indirect costs,
medical- or non-medical costs and how they are collected,
to guarantee valid interpretation and comparison with
other studies.16 In economic evaluations, costs refer to
the (monetary) value of anything that has to be sacrificed
in order to acquire something. In health economics, costs
usually reflect the expenditure of the healthcare system
on resources such as interventions, products, staff time,
and other consumables. The expenditures are quantified
in monetary terms, such as product cost and labour
cost.17 Total costs include all costs incurred in the produc-
tion of a set quantity of service. Which cost components
are incorporated depends on the objectives and context of
the evaluation.18 Key considerations are the economic
perspective (societal, institutional, insurer, or patient),
reflecting who is paying for the costs and the time hori-
zon (the duration over which health outcomes and costs
are calculated).19,20 The chosen time horizon is deter-
mined by the nature of the disease, the intervention
under consideration, and the purpose of the analysis.
Chronic conditions with a long-term treatment and
follow-up require longer time horizons opposed to acute
conditions requiring a shorter time horizon.16
Knowledge about the financial impact related to man-
agement of IAD can inform clinicians, individuals, and
policy-makers to make decisions regarding the correct
allocation of scarce healthcare resources and funding;
and can help health care workers focus on the timely
implementation of a cost-effective preventative/treatment
Key Messages
• this review demonstrates that there is a need
for specific methodological guidelines to con-
duct health economic studies and to provide a
core outcome set for monetary data
• this review demonstrates that for future
research it is important to include more health
economic analyses in research related to the
prevention and treatment of IAD, whereas
studies should not only focus on the cost-
effectiveness of the current best practices, but
also on comparing new technologies with each
other and with existing practices
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protocol to enhance patient quality care.20,21 A systematic
review on monetary data related to the management of
incontinence-associated dermatitis is however lacking.
1.1.3 | Aim
To systematically review monetary data related to man-
agement of IAD in an adult population.
2 | METHODS
2.1 | Design
A systematic review was conducted using the Cochrane
Collaboration guidelines for systematic reviews of inter-
ventions integrating economic evidence (The Cochrane
Collaboration, 2019). A review protocol was registered in
the PROSPERO database (number CRD42020163167).
2.2 | Search methods for identification of
studies
A four-step search strategy was applied to identify relevant
literature. Six electronic databases were systematically
searched: MEDLINE (using the PubMed interface), Cumu-
lative Index to Nursing and Allied Health Literature
(CINAHL) (using the EBSCO interface), Web of Science,
EMBASE (using the Embase.com interface), The Cochrane
Library and EconLit (using the EBSCO interface). Thereaf-
ter, conference proceedings of the annual European Pres-
sure Ulcer Advisory Panel (EPUAP) meetings (2003–2018)
and the European Wound Management Association
(EWMA) meetings (2001–2018) were screened. Next,
ClinicalTrials.gov and WHO International Clinical Trials
Registry Platform (ICTRP) were searched. Lastly, the refer-
ence lists of all included trials and other relevant literature
were screened to identify additional papers.
The search string included a combination of index
terms and text words using Boolean operators and was
TABLE 1 The search strategy for MEDLINE (using the PubMed interface)
Concept Line Search strategy
Incontinence-associated
dermatitis
1 “diaper rash”[MeSH] OR “diaper dermatitis”[TIAB] OR “diaper
erythema”[TIAB] OR “diaper rash*”[TIAB] OR “diaper wetness”[TIAB] OR
“napkin dermatitis”[TIAB] OR “napkin erythema”[TIAB] OR “napkin
rash*”[TIAB] OR “napkin wetness”[TIAB] OR “nappy dermatitis”[TIAB] OR
“nappy erythema”[TIAB] OR “nappy rash*”[TIAB] OR “nappy wetness”[TIAB]
OR “perineal dermatitis”[TIAB] OR “perineal erythema”[TIAB] OR “perineal
rash*”[TIAB] OR “perineal wetness”[TIAB] OR “incontinence-associated
dermatitis”[TIAB] OR “irritant contact dermatitis”[TIAB] OR “contact
dermatitis”[TIAB] OR “incontinence dermatitis”[TIAB] OR
“incontinenceassociated dermatitis”[TIAB] OR “IAD”[TIAB] OR “irritant
dermatitis”[TIAB] OR “incontinence skin”[TIAB] OR “incontinence
lesion*”[TIAB] OR “moisture lesion*”[TIAB] OR “moisture skin*”[TIAB] OR
“moisture-associated skin damage”[TIAB] OR “MASD”[TIAB] OR “moisture
maceration injur*”[TIAB] OR “intertrigo”[TIAB] OR “heat rash”[TIAB]
Health economics 2 “Economics”[MeSH] OR “cost analysis”[TIAB] OR “costs analyses”[TIAB] OR
“COI”[TIAB] OR “cost–benefit analysis”[TIAB] OR “cost allocation”[TIAB] OR
“cost control”[TIAB] OR “cost compar*”[TIAB] OR “cost sharing”[TIAB] OR
“cost of illness”[TIAB] OR “cost effect*”[TIAB] OR “hospital cost*”[TIAB] OR
“health care cost*”[TIAB] OR “cost*”[TIAB] OR “health economic*”[TIAB] OR
“economic*”[TIAB] OR “hospital economic*”[TIAB] OR “economic
advantage*”[TIAB] OR “nursing economic*”[TIAB] OR “economic
impact*”[TIAB] OR “costing”[TIAB] OR “medical care cost*”[TIAB] OR
“treatment cost*”[TIAB] OR “direct service cost*”[TIAB] OR “cost
measure*”[TIAB] OR “health expenditure*”[TIAB] OR “financing”[TIAB] OR
“public expenditure*”[TIAB] OR “health Insurance*”[TIAB] OR
“price*”[TIAB] OR “pricing”[TIAB] OR “budget*”[TIAB] OR
“insurance”[TIAB] OR “financial management”[TIAB] OR “economic
analysis”[TIAB] OR “economic analyses”[TIAB] OR “affordabilit*” [TIAB]
Filter/search block 3 None.
Combination of
concepts
4 #1 AND #2
Abbreviations: MeSH, medical subject headings; TIAB, title and abstract.
* = Truncation symbol, representing any group of characters, including no character.
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optimised with the support of a librarian technician. The
search filter for cost was based on the search filter of Neyt
and Chalon (2013) and was adapted to each database.22
When appropriate Medical Subject Headings or compara-
ble alternatives were used. The search strategy for
MEDLINE (using the PubMed interface) is represented
in Table 1. Retrieved records were imported in Endnote
and duplicates were removed using the duplicate search
function and by manually reviewing the list.
2.3 | Study eligibility
Title and abstract of all identified records were indepen-
dently screened for eligibility by two researchers using
Rayyan.23 Disagreements were discussed until consensus
was reached. Studies were included if the following criteria
were met: (a) targeting an adult population, in any
healthcare setting, with IAD (defined as erythema and
edema of the skin, sometimes accompanied by bullae with
serous exudate, erosion, or secondary cutaneous infection)
or at risk for developing IAD; (b) providing monetary data
of at least the direct medical cost of IAD prevention or
treatment; (c) retrieved from the original research, or
health economic modelling using data from international
literature. There were no restrictions with respect to lan-
guage, date of publication or study setting. Papers were
excluded if (a) they only discussed other wounds and not
IAD; (b) if they exclusively reported on caregiver time;
(c) if they reported about interventions and products not
being applied in health care.
2.4 | Data extraction
A data extraction table was developed including author
details, year of publication, intervention, prevention and/or
treatment focus, country and currency, fiscal year of data
collection, sample size, IAD classification, type of health
economic study (cost-effectiveness analysis, cost-utility
analysis, cost–benefit analysis, outcome description; cost
description; cost outcome description; effectiveness evalua-
tion; cost analysis), time horizon, economic perspective
(societal, institution, patient, or insurance perspective),
type of cost (direct medical, non-direct medical, direct
non-medical, or non-direct non-medical), cost-related mea-
surements, outcomes, and converted costs. Data extraction
was completed independently by two reviewers. Disagree-
ments were discussed until consensus was reached.
2.5 | Quality assessment
Included articles were assessed for methodical quality
using the Consensus Health Economic Criteria (CHEC-)
list; a 19-point checklist to assess economic evaluation
studies. The CHEC-list is suitable for systematic reviews
including full economic evaluation studies and partial
economic evaluation studies based on clinical trials
(cohort studies, case–control studies, randomised con-
trolled clinical trials).24 A quality assurance was com-
pleted independently by a second reviewer. The level of
agreement between both assessors was calculated using
the Cohen's Kappa correlation.25 Disagreements were dis-
cussed until consensus was reached. When necessary, a
third reviewer was consulted. Because of the scope of this
review, the methodological quality of the studies was no
reason for exclusion.
2.6 | Data collection and analysis
Monetary data were extracted from the included stud-
ies. Original data were converted to 2018 US$ using
the Campbell and Cochrane Economics Methods
Group (CCEMG)-Evidence for Policy and Practice
Information and Co-ordinating Centre (EPPI-centre)-
Converter.26 If studies did not report the reference
year of the data collection, the year before the article
was published was used as reference. When studies
did not report the country of data collection the USA
and US$ were used to convert the original data.
Because of methodological heterogeneity, results were
synthesised narratively, and no meta-analysis was
performed.
3 | RESULTS
In total, 1374 records were retrieved from systematic
searches in databases (436 in PubMed, 69 in CINAHL,
223 Web of Science, 349 EMBASE, 2 in Econlit and
295 in the Cochrane Library). Removal of duplicates
resulted in 1025 potentially relevant records. Of these,
964 records were excluded after screening of title and
abstract, and 52 records were assessed for full text screen-
ing. After identifying records through other sources, nine
articles were included in the review. The PRISMA flow-
chart27 is summarised in Figure 1.
The level of agreement (Cohen's Kappa correlation)
between the authors was 0.96. Disagreements were dis-
cussed until consensus was reached. An overview of the
quality assessment is presented in Table 2. One article
reported the chosen perspective.28 In six studies, the time
horizon was in agreement with the research question.
Relevant costs related to the research question were
reported in all studies. Expenditures were expressed in
product costs, labour cost, and total cost. In one study,
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costs were not measured and valued appropriately in
physical units.29 Five studies used a validated scale to
assess IAD. An incremental analysis was performed in
one study,30 and in none of the studies a sensitivity analy-
sis was performed. Conclusions followed from the
reported data in all studies. Generalizability of the study
outcomes were discussed in eight studies.
3.1 | Study characteristics
The included studies focused on IAD prevention
(n = 7)28,29,31-35, IAD treatment (n = 1)36 or both (n = 1)30.
Studies were performed in nursing homes (n = 6)28-30,32-34,
long-term care facilities (n = 1)36, and acute and intensive
care (n = 2)31,35. Countries of study were the United States
FIGURE 1 PRISMA flowchart


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































RAEPSAET ET AL. 7
of America (USA) (n = 5)29,32,34-36, Turkey (n = 1)31, Italy
(n = 1)33, the Netherlands (n = 1)30, and the United
Kingdom (UK) (n = 1)28. All studies used different skin
assessment tools, of which five were validated. Sample
sizes varied between 10 and 981. Time horizons varied
between 4 days and 7 months. Only Bale et al. (2004) spec-
ified the economic perspective (societal perspective includ-
ing the National Health Services). A full economic study
design was performed in all studies. The main study char-
acteristics are provided in Table 3.
3.2 | The cost of IAD prevention
3.2.1 | Skin cleansing
Three interventions included skin cleansing. Two inter-
ventions were tested in a nursing home and one in an
acute care setting. The cost of the interventions is pro-
vided in Table 4. The product cost for one intervention
was reported. The use of liquid antiseptic soap
(Chlorhexidine 4,0%) and water in an acute care unit
(ACU) resulted in a product cost of $20.03 per patient per
day. The labour cost for the intervention per patient per
day was $57.51, and the total cost was $142.92. The
labour cost included repositioning, mobilisation, chang-
ing bed sheets, skin care, and documentation. No costs
per application were reported.
In nursing homes, the labour cost for cleansing the
skin in case of an episode of urine incontinence ranged
between $0.30 (no-rinse cleanser) and $1.29 (water and
soap), while the labour cost for cleansing the skin in case
of an episode of faeces and urine incontinence ranged
between $0.85 (no-rinse cleanser) and $3.62 (water and
soap). For both interventions, no labour costs per patient
per day were reported. No total costs were provided for
the interventions tested in the nursing homes.
3.2.2 | Skin cleansing and protection
Seven interventions included skin cleansing and skin
protection. Six interventions, of which four were tested in
a nursing home, included a two-step procedure to cleanse
and protect the skin. One intervention included a one-
step procedure and was tested in an ACU. The cost of the
interventions is provided in Table 4.
The product cost per patient per day in an ACU ranged
between $7.41 (no-rinse cleanser followed by a film poly-
meric solution spray) and $20.17 (cleansing wipes followed
by a barrier cream/spray) for a two-step procedure, while
a product cost per patient per day of $3.00 was reported
when using an one-step cleanser, moisturiser, barrier
washcloth (with 3% dimethicone) in an ACU. In nursing
homes, the product cost per patient per day using a two-
step procedure ranged between $2.36 (water and soap
followed by a protective cosmetic cream [Drapolene,
Nivea]) and $4.73 (no-rinse cleanser followed by a durable
moisture barrier cream). For none of the interventions,
product costs per application were reported.
Labour and total cost were reported for one interven-
tion. The use of cleaning wipes followed by a barrier cream/
spray in an ACU resulted in a labour cost per patient per
day of $72.94, and a total cost per patient per day of
$114.48. Labour cost included repositioning, mobilisation,
changing bed sheets, skin care, and documentation.
3.2.3 | Skin protection
Eight interventions included skin protection and were
tested in a nursing home. The cost of the interventions is
provided in Table 4.
Skin protectants included an acrylate terpolymer-
based barrier film (spray) (n = 3), petrolatum ointments
(n = 4), and a protectant cream with 12% zinc oxide and
1% dimethicone (n = 1). The product cost per application
ranged between $0.05 (acrylate terpolymer-based barrier
film 3x/week) and $0.52 (acrylate terpolymer-based bar-
rier film 1x/daily). The product cost per patient per day
ranged between $0.23 (acrylate terpolymer-based barrier
film 3x/week) and $1.86 (12% zinc oxide and 1%
dimethicone cream per incontinent episode).
The labour cost per application ranged between $0.01
(acrylate terpolymer-based barrier film 3x/week) and
$0.28 (acrylate terpolymer-based barrier film 1x/daily),
and ranged per patient per day between $0.16 (acrylate
terpolymer-based barrier film 3x/week) and $1.26 (12%
zinc oxide and 1% dimethicone cream). The total cost per
application ranged between $0.06 (acrylate terpolymer-
based barrier film 3x/week) and $0.80 (acrylate
terpolymer-based barrier film 1x/daily), while the total
cost per patient per day ranged between $0.35 (acrylate
terpolymer-based barrier film 3x/week) and $2.94 (43%
petrolatum ointment).
Two interventions introduced a new incontinence
material and a structured skin care program in nursing
homes. The cost of the interventions is provided in
Table 4.
A product cost per patient per day of $3.41 was
reported for a prevention protocol using polymer inconti-
nence material and a skin care regime (depending on the
type of incontinence). The product cost per patient per
day for the same protocol followed by the advice provided
by continence nurses was $1.92. The labour cost per
patient per day for the intervention—without the advice







































































































































































































































































































































































































































































































































































































































































































































































































































RAEPSAET ET AL. 9
provided by continence nurses—was $5.93, while with
the advice, the labour cost per patient per day was $3.16.
Labour cost, included changing of incontinence material
and skin care. Total costs were not reported.
3.3 | Cost of treatment
3.3.1 | Skin cleansing and protection
Three interventions included skin cleansing and protec-
tion and were performed in a long-term care setting. Two
interventions contained a two-step procedure and one
intervention contained a one-step barrier lotion spray.
The cost of the interventions is provided in Table 4.
The product cost per application for a two-step proce-
dure ranged between $0.28 (no-rinse cleanser and pre-
moistened soft, disposable, non-woven cleaning wipes
followed by a skin barrier paste) and $0.35 (no-rinse
cleanser or pre-moistened soft, disposable, non-woven
cleaning wipes followed by an antifungal cream). For a
one-step procedure using a one-step barrier lotion spray,
product cost per application of $0.20 was reported. No
product costs per patient per day were provided.
For the two-step procedures, labour cost per applica-
tion ranged between $0.48 (no-rinse cleanser or pre-
moistened soft, disposable, non-woven cleaning wipes
followed by an antifungal cream) and $0.91 (no-rinse
cleanser and pre-moistened soft, disposable, non-woven
cleaning wipes followed by a skin barrier paste). The
application of a one-step barrier lotion spray resulted in a
labour cost per application of $0.50. Labour cost included
cleansing the perineal area and the time spent applying
the protectant. Labour costs per patient per day were not
reported. For none of the interventions a total cost was
provided.
3.4 | Cost of combined prevention and
treatment
3.4.1 | Skin protection
Two interventions focused on the application of a skin
protectant and were tested in nursing homes (Table 4).
The product cost per patient per day ranged between
$0.57 (acrylate terpolymer-based barrier film, application
frequency in accordance with skin score) and $1.08 (zinc
oxide oil). The labour cost per patient per day ranged
between $5.24 (acrylate terpolymer-based barrier film)
and $6.74 (zinc oxide oil).
Labour cost included removing the protectant, wash-
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protectant. The total cost per patient per day ranged
between $5.81 (acrylate terpolymer-based barrier film)
and $7.87 (zinc oxide oil). No product, labour, and total
costs per application were provided.
4 | DISCUSSION
The aim was to systematically review monetary data
related to management of incontinence-associated der-
matitis in an adult population. Skin damage because of
urine and/or faecal exposure can be reduced by applying
protocols focusing on incontinence management and the
application of a structured skin care regimen (cleansing,
protecting, and restoring the skin at risk).9 Nine articles
were included in this review. Only direct medical costs
were reported. The product cost per application for pre-
vention ranged between $0.05 and $0.52. The product
cost per application for treatment ranged between $0.20
and $0.35. The product cost per patient/day for preven-
tion ranged between $0.23 and $20.17. The product cost
of IAD prevention and treatment per patient/day ranged
between $0.57 and $1.08. The cost to treat IAD did not
fully consider the systemic treatment of IAD-associated
infection (bacterial/fungal). The calculation of labour
cost and total cost differed considerably between studies.
Therefore, an interpretation of the labour and total cost
of IAD prevention and/or treatment is challenging.
Variation in reported costs are related to methodolog-
ical differences between studies, such as cost value
(e.g. cost per patient per day vs cost per episode of incon-
tinence), items included in the labour and total cost cal-
culations, types of skin care products studied, and
different health systems and economic contexts (USA vs
UK vs Europe). For that reason, directly compare find-
ings between studies is challenging.
Adequate education of nursing staff and the use of
effective interventions are the first concern to prevent
and treat IAD. The next step is to evaluate the associated
costs because of the high prevalence of IAD and the sub-
stantial number of persons being at risk for developing
IAD. Water and soap are non-expensive resources for
skin cleansing. However, a no-rinse cleanser is less
expensive because of low labour cost ($0.85 versus $3.62
per episode of faecal and urine incontinence).29 32 For
skin protection the results indicate that, for both product
and labour cost, the acrylate terpolymer-based barrier
film applied 3 times a week could be a cost-effective skin
protectant to prevent and treat IAD.30 32 34 In the treat-
ment of IAD, a one-step barrier lotion spray (combined
product) appears to be less expensive in terms of product
and labour cost, but the average time to skin breakdown
was longer for a two-step procedure, using a no-rinse
cleanser in combination with a barrier film.35,36 This
review demonstrated that skin care is an area of nursing
practice where savings can be made by introducing a
structured approach (including a structured skin care
program, education, and nursing advice).31
4.1 | Limitations of the study
Because of the methodological heterogeneity of the
extracted data, only a narrative synthesis was possible.
Heterogeneity was found in country, currency, setting,
sample, time horizon, health- and cost outcome valua-
tion, measurement, and total cost explanations. It is
important to note that every country has its own specific
guidelines for performing economic evaluations and a
lack of detailed and transparent reporting hindered the
interpretation of the cost of IAD prevention and/or treat-
ment. Most studies in the review were published before
201128-30,32,34,36 and the interventions and knowledge on
IAD development may have changed. Therefore, the
results of this review need to be interpreted with caution.
Despite only one study reported the economic
perspective,28 it is a key consideration in economic evalua-
tions. Health economics recommend the inclusion of soci-
etal perspective in economic evaluations because of the
consistency and comparability.37 The societal perspective
includes indirect non-medical costs (eg, absenteeism) and
minimises the potential bias of narrow perspectives.16,38
Even though the economic impact of indirect costs on the
social expenditures may be negligible for IAD, it could be
valuable to include indirect medical costs (future costs
related to other diseases) in future studies.16
Pressure ulcer development and associated costs can
be minimised by decreasing IAD as a risk factor. Even
though not all people who develop IAD will develop a
pressure ulcer, a systematic review and meta-analysis con-
ducted by Beeckman et al. (2014) indicated an association
between the etiologic factors and the pathogenesis of IAD
and the development of pressure ulcers. 39,40 The exposure
to moisture and irritants changes the mechanical skin
properties and underlying tissue by diminishing the cross-
links between the collagen in the dermis and by softening
the stratum corneum.41 Additionally, moisture increases
the skin's coefficient of friction and increases the exposure
of underlying blood vessels to the effects of pressure.
By including a more comprehensive and inclusive set
of direct medical costs (cost of linen changes, skin
cleansers and protectants, cost of labour, …) and taking
into account indirect medical costs, future studies can
provide a view on the total impact of IAD prevention and
treatment. Another key consideration is the applied time
horizon. Among the studies, time horizons varied
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between 4 days and 7 months and none of the studies
used identical time horizons. Guidelines suggest that time
horizons should cover a lifetime to include all health and
cost outcomes. Shorter time horizons are appropriate if
justified.42 The time horizon of incontinence-associated
dermatitis cannot be compared with the time horizon of a
chronic disease where long time horizons are appropri-
ate. No research is available on what the ideal time hori-
zon should be for IAD development and/or treatment;
therefore, future trials can explore this concept.
This review highlighted the lack of a standardised,
valid, method to measure and report costs. There was a
considerable lack of detail when describing labour and total
costs. It was challenging to identify which cost components
were included in labour and total cost. Additionally, cost
values (e.g. cost per application, cost per patient per day)
were not consistent and only Byers et al. (1995) separated
costs for urine and faecal incontinence.29 The results of this
review encourage to incorporate monetary data into a Core
Outcome Set (COS). A COS is a consensus-derived set of
outcomes that includes the minimum that should be
reported in all clinical trials in a specific disease or popula-
tion. It encompasses a core domain set (defining what core
outcomes should be measured) and a core measurement
set (defining measurement/assessment instruments for
each core domain).36 Using identical outcomes across trials
allow comparability of results, increases the value of evi-
dence synthesis, and decreases the risk of outcome
reporting bias.43 By incorporating monetary data into a
COS, data collection can be standardised and improved,
which will aid the process determining the cost-
effectiveness of products and interventions.
This review emphasised the importance to include
more health economic analyses in research related to the
prevention and treatment of IAD. It is well documented
that many countries have a challenge with nurse scarcities
and a high staff turnover.12,13 By using evidence-based pre-
vention/interventions to avoid skin breakdown, cost can
be saved in nursing time, and also free up nursing time to
tend to other patient-related tasks. Furthermore, new tech-
nologies such as cyanoacrylate-based formulations have
been developed to serve as an advanced skin protectant.44
Therefore, future studies should not only focus on the
cost-effectiveness of the current best practices, but also on
comparing new technologies.
5 | CONCLUSION
Prevention and treatment of IAD are associated with a
significant cost. Summarising monetary data is a chal-
lenge because of heterogeneity in currencies, settings,
samples, time horizons, health- and cost outcome
valuation, IAD definition and measurements and which
costs are included (product costs with/without labour
costs). Only direct medical costs are reported. The cost to
treat IAD does not fully consider the systemic treatment
of IAD associated infection (bacterial/fungal). Procedures
for health economic evaluations are to be clarified to
guarantee valid interpretation and comparison with other
studies.
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